The Clinical Value of Leukocyte-Reduced Blood Component Transfusion in the Treatment of Elderly Cancer Patients

Article ID: 4701

Keywords: Elderly cancer patients; Transfusion therapy; Leukocyte-reduced blood components; Clinical value

Abstract

Objective: This study aims to evaluate the clinical value of leukocyte-reduced blood component transfusion in elderly cancer patients undergoing transfusion therapy. Methods: A total of 80 elderly cancer patients who received transfusion therapy in our hospital between August 2022 and August 2023 were enrolled. Based on transfusion methods, patients were divided into a control group (n=40, conventional suspended red blood cell transfusion) and an experimental group (n=40, leukocyte-reduced component transfusion). Treatment efficacy, incidence of adverse reactions, postoperative infection rate, and surgical incision healing time were compared between the two groups. Results: The experimental group showed significantly higher clinical efficacy, a lower incidence of adverse reactions and postoperative infections, and a shorter incision healing time compared to the control group. The differences were statistically significant (P < 0.05). Conclusion: Leukocyte-reduced component transfusion meets the clinical needs of elderly cancer patients, significantly improves treatment efficacy, reduces adverse reactions and infections, and shortens incision healing time. It is therefore recommended for wider clinical adoption.